Full-Time

Zonal Market Access Manager

Posted on 9/7/2026

Deadline 9/30/26
Sanofi

Sanofi

10,001+ employees

Global pharma company; vaccines and R&D

No salary listed

Mumbai, Maharashtra, India

In Person

Regular travel to state capitals and key cities, with occasional travel to national headquarters.

Bachelor's, Master's, MBA

Category
Business & Strategy
Required Skills
Supply Chain Management

Get referred to Sanofi

See people who can refer or advise you

Requirements
  • A bachelor's degree in pharmacy, life sciences, business, public health, or a related field is required.
  • Eight to ten years of pharmaceutical or healthcare industry experience is required.
  • The candidate must have a proven track record in state-level stakeholder engagement, including examples of state or central interim funding or reduced timelines for formulary listing or reimbursement committee processes.
  • Experience managing access programs and payer negotiations for specialty or innovative therapies is required.
  • The candidate must understand Indian state healthcare systems and approaches to innovative therapy access.
  • Experience in market access, government affairs, or payer relations is advantageous.
  • The candidate must be able to navigate complex state bureaucracies.
  • The candidate must demonstrate regional market access strategy execution for innovative therapies.
  • The candidate must demonstrate state-level payer engagement for specialty products.
  • The candidate must demonstrate health economics and value demonstration for breakthrough immunology therapies.
  • The candidate must demonstrate strategic planning and execution for innovative product launches.
  • The candidate must have project management and program delivery capabilities in complex healthcare environments.
  • The candidate must have stakeholder relationship management capabilities focused on innovative therapy access.
  • The candidate must be able to communicate access value evidence and collaborate cross-functionally.
  • Regular travel to state capitals and key cities is required, along with occasional travel to national headquarters.
  • Regional language skills are an advantage.
Responsibilities
  • Identify, analyze, and strategically pursue state and central government funding opportunities for specialty and innovative therapies, including Rare Disease treatments, Qfitlia, and the Transplant portfolio.
  • Build relationships with state health departments and finance ministries to secure funding for the specialty portfolio.
  • Develop and implement funding proposals for state health departments and finance ministries that demonstrate clinical value and economic benefits.
  • Navigate state health schemes and budget allocation processes to secure sustainable funding pathways for specialized therapies.
  • Lead initiatives to include the company's portfolio in state essential medicine lists and formularies through evidence-based advocacy.
  • Monitor and analyze healthcare budget cycles to optimize the timing of funding requests and proposals.
  • Lead engagement with state insurance schemes and regional payers by communicating the value proposition of specialty and innovative therapies.
  • Co-create and present access value dossiers tailored to regional needs, emphasizing the clinical and economic benefits of innovative immunology therapies.
  • Drive product inclusion in regional institution formularies to secure access for breakthrough treatments.
  • Track and analyze payer policy developments and incorporate insights into regional access plans to accelerate formulary listings.
  • Build state advocacy and replicate successful approaches across states.
  • Build relationships with state health officials and commissioners to advocate for innovative immunology treatments.
  • Collaborate with public health organizations to address unmet needs in immunology.
  • Execute regional market access plans aligned with national strategy for Rare Disease, transplant, immunology, diabetes, and specialty pipeline products.
  • Translate national objectives into actionable regional plans for innovative therapies.
  • Provide regional insights to inform national strategy for the immunology portfolio.
  • Support national policy advocacy efforts focused on innovative treatment access.
  • Represent the company at regional healthcare forums, policy discussions, and industry events.
  • Partner with regional sales teams to obtain market intelligence on the immunology treatment landscape.
  • Collaborate with medical affairs on regional key opinion leader engagement for innovative therapies.
  • Work with marketing on regional campaigns highlighting breakthrough treatments.
  • Coordinate with supply chain on product availability for current and future launches.
Desired Qualifications
  • An MBA or master's degree in healthcare management or public health is preferred.
  • An advanced degree in health economics or public policy is preferred.
  • Multi-state or regional experience across India is preferred.
  • Knowledge of state funding and formulary listing processes for specialty medicines is preferred.
  • Experience designing patient support programs for innovative therapies is preferred.
  • Understanding regional insurance schemes and their approach to breakthrough treatments is preferred.

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 2026 sales rose 13.6%, while launches grew 49.6% and Dupixent 30.8%.
  • July 2026 FDA approval expanded Sarclisa across all U.S. myeloma indications.
  • Paulo Fontoura assumed R&D leadership on September 1, 2026, accelerating pipeline execution.

What critics are saying

  • Tolebrutinib’s FDA rejection on December 24, 2025 exposed severe liver-injury risk.
  • Dupixent lawsuits consolidated in New Jersey by June 2026 threaten label and damages exposure.
  • Sanofi’s insulin plant needed €400 million German aid on September 8, 2026, signaling supply fragility.

What makes Sanofi unique

  • Dupixent posted €4.17 billion Q1 2026 sales, dominating immunology globally.
  • Sanofi’s July 2026 Sarclisa Escena became the first cancer on-body injector treatment.
  • Sanofi secured Cenrifki EU approval in June 2026, advancing a differentiated MS franchise.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Parental Leave

Company News

La Croix
Sep 8th, 2026
EU approves $448M German subsidy to Sanofi for insulin production security

The European Commission has approved a €400 million subsidy from Germany to pharmaceutical company Sanofi to maintain its Frankfurt insulin production site. The Commission stated that without this aid, Sanofi would close the German facility, reducing insulin supply security across the European Economic Area. The subsidy aims to compensate Sanofi for costs related to a service of general economic interest, strengthening insulin supply resilience for German patients. In return, Sanofi must build a new insulin factory in Frankfurt by 31 December 2032 and guarantee minimum annual production of 1.1 tonnes until 2042. Sanofi is among the world's leading insulin producers. The company announced in 2024 a €1.3 billion investment in Frankfurt to construct a new complex replacing existing facilities.

StreetInsider
Aug 25th, 2026
Altesa BioSciences wins award for oversubscribed $75M Series B to advance COPD therapies

Atlanta-based Altesa BioSciences has won the 2026 Georgia Life Sciences Golden Helix Award for Deal of the Year, recognising its oversubscribed $75 million Series B financing round. The funding, led by Forbion with participation from Sanofi, Medicxi, Pitango, and Atlantic Partners, will advance the clinical-stage pharmaceutical company's lead therapy, vapendavir. Vapendavir is an investigational oral treatment for chronic lung diseases including COPD and asthma. The drug is currently being evaluated in the Phase 2b CARDINAL trial, which will enrol 900 COPD patients across the US and UK. The Georgia Research Alliance Venture Fund was an early investor in Altesa. The company's scientific founders previously helped develop molnupiravir, one of the earliest COVID-19 treatments.

Business Wire
Aug 13th, 2026
Epicrispr Biotechnologies Closes $90 Million Oversubscribed Series C Financing to Advance First-in-Class Epigenetic Therapy Toward Pivotal Studies in FSHD

Epicrispr Biotechnologies Closes $90 Million Series C Financing to Advance First-in-Class Epigenetic Therapy Toward Pivotal Studies in FSHD

Morningstar
Aug 12th, 2026
InduPro raises $77M Series B, doses first patient in Phase 1 trial of bispecific ADC for lung cancer

InduPro has closed a $77 million Series B financing round and dosed its first patient in a Phase 1 study of IDP-001, its lead oncology programme. The biotechnology company is developing IDP-001, a bispecific antibody-drug conjugate targeting EGFR and a novel tumour-associated proximity antigen, for treating advanced squamous non-small cell lung cancer and other solid tumours. The Column Group led the financing round, with participation from Vida Ventures, MRL Ventures Fund, Emerson Collective, Euclidean Capital, Solasta Ventures, Sanofi, and Eli Lilly and Company. Proceeds will support Phase 1 clinical development and early proof-of-concept data generation for IDP-001, whilst advancing InduPro's broader preclinical pipeline. InduPro uses a proximity-guided platform to map protein spatial relationships on cell surfaces for discovering selective co-target pairs.

FinancialContent
Jul 24th, 2026
Scribe Therapeutics prices upsized $129M IPO at top of range

Scribe Therapeutics, a clinical-stage biotechnology company developing in vivo CRISPR technologies, has priced its upsized initial public offering at $15.00 per share, the high end of its range. The company is offering 8,580,000 shares, expecting to raise $128.7 million in gross proceeds before fees and expenses. Scribe has also granted underwriters a 30-day option to purchase up to 1,287,000 additional shares. The shares are expected to begin trading on the Nasdaq Global Market on 24 July 2026 under the ticker symbol "SCTX", with the offering closing on 27 July 2026. Additionally, Scribe has agreed to sell 500,000 shares at the same price to Sanofi in a concurrent private placement. Leerink Partners, Goldman Sachs, Guggenheim Securities, and Wells Fargo Securities are serving as joint book-running managers.